Clinical trials: MCD
Interstitial Lung Disease
The Role of KL-6 in the Clinical Diagnosis of ILD
The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the…
- Trial name
- NCT02197364
- Volunteers
- 1,190 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Obesity
Mindful Construal Diaries: Can the MCD Increase Mindfulness and Mindful Eating in Bariatric Surgery Patients
The study aims to test the Mindful Construal Diary (MCD- a mindful eating intervention) initially developed by Mantzios and Wilson.
- Trial name
- NCT03822481
- Testing
- Mindful Construal Diary
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Birmingham City University
Breast Cancer, Anthropometric Measurements
2D:4D Finger Ratio and Breast Cancer in Women
This prospective study aims to evaluate the 2D:4D finger ratio in women diagnosed with breast cancer compared to healthy controls and to examine its potential association with tumor markers, including carcinoembryonic antigen…
- Conditions
- Breast Cancer, Anthropometric Measurements, Females
- Trial name
- NCT07436169
- Where
- Turkey (Türkiye)
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Malatya Turgut Ozal University
Brain and Central Nervous System Tumors, Breast Cancer
Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome
RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer or meningeal syndrome may help doctors identify biomarkers related to cancer.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Metastatic Cancer
- Trial name
- NCT00938756
- Testing
- diagnostic laboratory biomarker analysis, immunoenzyme technique, magnetic resonance imaging
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Oscar Lambret
Multicentric Castleman Disease
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial.
- Trial name
- NCT04585893
- Testing
- Rituximab, Etoposide
- Where
- Malawi
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Interstitial Lung Disease, Desquamative
Sequential Changes of Serum KL-6 Predict Progression in Interstitial Lung Disease
Interstitial lung disease is a chronic progressive fibrosis lung disease that with a highly variable clinical process.thence it is significant for the patient to search a convenient and accurate prediction method.
- Trial name
- NCT02960672
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Minimal Change Disease
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in…
- Trial name
- NCT06405100
- Testing
- Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab
- Volunteers
- 81 people
- Sponsor
- Air Force Military Medical University, China
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Microvascular Coronary Dysfunction
Cardiac Autonomic Function in Women with Microvascular Coronary Dysfunction
Microvascular coronary dysfunction (MCD) (abnormities in small blood vessels/arteries in heart) with symptoms of persistent chest pain impacts women.
- Trial name
- NCT01568177
- Testing
- Mental Stress Testing, Peripheral Arterial Tonometry (PAT) Testing, Heart Rate Variability (HRV)
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Minimal Change Disease (MCD)
A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab.
- Trial name
- OBELIX-NS (NCT07710157)
- Testing
- Obinutuzumab Injection, Predniso(lo)ne
- Where
- 6 sites in Austria, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Medical University Innsbruck
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Idiopathic Pulmonary Fibrosis
Longitudinal Changes in Serum KL-6 in IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis. More accurate tests to predict disease progression and response to treatment are required.
- Trial name
- LOCK-IPF (NCT04268485)
- Testing
- Serum KL-6 level
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Manchester University NHS Foundation Trust
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Pulmonary Fibrosis
Diagnostic Value of KL-6 in ILD
KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations.
- Trial name
- NCT03103191
- Testing
- KL-6 levels
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN.
- Conditions
- Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07614477
- Testing
- EVER001
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid…
- Trial name
- NCT05441826
- Testing
- VB119
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tenet Medicines
Acute Viral Bronchiolitis
KL-6 Protein as a Biomarker of Lung Injury in Viral Bronchiolitis
Serum KL-6 protein has been described as a biomarker of epithelial lung injury in Respiratory Syncytial Virus bronchiolitis. The investigators can imagine that epithelial injury intensity has consequences on immediate and later…
- Trial name
- NCT01437956
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Breast Cancer
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
The purpose of this research study is to study the effects of using aromatase inhibitor (AI) therapy intermittently on participants with breast cancer. AIs are a class of drugs used to treat breast cancer in postmenopausal women.
- Trial name
- NCT00549822
- Testing
- Letrozole
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital